Inspire Q1 2025 Earnings Report
Key Takeaways
Inspire Medical Systems reported strong performance in the first quarter of 2025 with revenue growth of 23% year-over-year, reaching $201.3 million. The company achieved a net income of $3.0 million and diluted earnings per share of $0.10, showing significant improvement compared to a net loss in the prior year period. Gross margin remained strong at 84.7%, and operating loss improved by 90%. The company also surpassed a milestone of 100,000 patients receiving Inspire therapy.
Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last year.
Achieved gross margin of 84.7% in the first quarter of 2025.
Generated earnings per share of $0.10 in the first quarter of 2025.
Surpassed 100,000 patients receiving Inspire therapy.
Inspire
Inspire
Inspire Revenue by Geographic Location
Forward Guidance
Inspire is maintaining its full year 2025 revenue guidance and gross margin guidance, while increasing its diluted net income per share guidance.
Positive Outlook
- Maintaining full year 2025 revenue guidance of $940 million to $955 million.
- Maintaining full year 2025 gross margin guidance of 84% to 86%.
- Increasing diluted net income per share guidance for full year 2025 to between $2.20 to $2.30.
- Initiating the full launch of the Inspire V system in the U.S. this month.
Revenue & Expenses
Visualization of income flow from segment revenue to net income